Vera Therapeutics Inc
VERA20.160USD
-0.790-3.77%
交易中 （美东）报价延迟15分钟
1.29B总市值
亏损市盈率 TTM
关于 Vera Therapeutics Inc 公司
Vera Therapeutics, Inc. 是一家后期生物技术公司。该公司专注于开发和商业化针对严重免疫疾病患者的变革性疗法。其主要候选产品是阿塞西普，这是一种融合蛋白，每周皮下注射一次，可阻断 B 细胞活化因子 (BAFF) 和 A 增殖诱导配体 (APRIL)，后者可刺激 B 细胞产生自身抗体，导致某些自身免疫性疾病，包括 IgAN（也称为伯杰氏病）和狼疮性肾炎。此外，该公司正在评估其他疾病，在这些疾病中，阿塞西普减少自身抗体可能具有医学用途。该公司还致力于开发 MAU868，这是一种单克隆抗体，旨在中和 BK 病毒 (BKV) 感染，BKV 是一种多瘤病毒，在某些情况下（例如肾移植）可能会造成毁灭性后果。该公司保留阿塞西普和 MAU868 的所有全球开发和商业权利。
公司简介
公司代码VERA
公司名称Vera Therapeutics Inc
上市日期May 14, 2021
CEODr. Marshall Fordyce, M.D.
员工数量112
证券类型Ordinary Share
年结日May 14
公司地址2000 Sierra Point Parkway, Suite 1200
城市BRISBANE
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编94005
电话16507700077
网址https://veratx.com/
公司代码VERA
上市日期May 14, 2021
CEODr. Marshall Fordyce, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Marshall Fordyce, M.D.
Dr. Marshall Fordyce, M.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
287.51K
-9.77%
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
135.56K
-89.68%
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
Independent Director
Independent Director
17.49K
--
Ms. Christy Oliger
Ms. Christy Oliger
Independent Director
Independent Director
--
--
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. William D. Turner
Mr. William D. Turner
Chief Development Officer
Chief Development Officer
--
--
Mr. David Louis Johnson
Mr. David Louis Johnson
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Sean P. Grant
Mr. Sean P. Grant
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Kimball Hall
Ms. Kimball Hall
Independent Director
Independent Director
--
--
Dr. Robert M. (Rob) Brenner, M.D.
Dr. Robert M. (Rob) Brenner, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Marshall Fordyce, M.D.
Dr. Marshall Fordyce, M.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
287.51K
-9.77%
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
135.56K
-89.68%
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
Independent Director
Independent Director
17.49K
--
Ms. Christy Oliger
Ms. Christy Oliger
Independent Director
Independent Director
--
--
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. William D. Turner
Mr. William D. Turner
Chief Development Officer
Chief Development Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月28日 周一
更新时间: 7月28日 周一
持股股东
股东类型
持股股东
持股股东
占比
Avoro Capital Advisors LLC
8.94%
Longitude Capital Management Co., LLC
8.07%
T. Rowe Price Associates, Inc.
7.36%
BlackRock Institutional Trust Company, N.A.
5.62%
Deerfield Management Company, L.P.
5.25%
Other
64.76%
持股股东
持股股东
占比
Avoro Capital Advisors LLC
8.94%
Longitude Capital Management Co., LLC
8.07%
T. Rowe Price Associates, Inc.
7.36%
BlackRock Institutional Trust Company, N.A.
5.62%
Deerfield Management Company, L.P.
5.25%
Other
64.76%
股东类型
持股股东
占比
Investment Advisor
34.41%
Hedge Fund
31.30%
Investment Advisor/Hedge Fund
30.28%
Venture Capital
12.85%
Corporation
3.00%
Research Firm
2.19%
Individual Investor
1.05%
Private Equity
0.75%
Pension Fund
0.23%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
380
74.98M
117.56%
-3.36M
2025Q1
382
72.82M
114.18%
-4.50M
2024Q4
363
73.64M
115.55%
+5.56M
2024Q3
344
64.32M
116.69%
-4.00M
2024Q2
326
63.69M
115.63%
-1.15M
2024Q1
280
61.43M
112.19%
+9.50M
2023Q4
210
49.91M
111.09%
+1.94M
2023Q3
190
48.72M
112.47%
-1.60M
2023Q2
180
47.50M
110.63%
+142.39K
2023Q1
161
46.72M
108.87%
+12.76M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Avoro Capital Advisors LLC
5.70M
8.94%
+91.90K
+1.64%
Mar 31, 2025
Longitude Capital Management Co., LLC
5.14M
8.07%
--
--
Oct 31, 2024
T. Rowe Price Associates, Inc.
4.70M
7.36%
+373.15K
+8.63%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.59M
5.62%
+33.98K
+0.96%
Mar 31, 2025
Deerfield Management Company, L.P.
3.35M
5.25%
+2.30M
+218.87%
Jun 06, 2025
Fidelity Management & Research Company LLC
3.23M
5.07%
+179.19K
+5.87%
Mar 31, 2025
The Vanguard Group, Inc.
2.91M
4.56%
-31.14K
-1.06%
Mar 31, 2025
Sofinnova Investments, Inc
2.79M
4.38%
--
--
Mar 31, 2025
Commodore Capital LP
2.56M
4.02%
+603.18K
+30.80%
Mar 31, 2025
Vestal Point Capital, LP
2.50M
3.92%
+1.43M
+132.56%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
ALPS Medical Breakthroughs ETF
1.02%
Virtus LifeSci Biotech Clinical Trials ETF
0.94%
SPDR S&P Biotech ETF
0.43%
Direxion Daily S&P Biotech Bull 3X Shares
0.25%
ProShares Ultra Nasdaq Biotechnology
0.17%
Invesco Nasdaq Biotechnology ETF
0.17%
iShares Biotechnology ETF
0.12%
T Rowe Price Small-Mid Cap ETF
0.08%
iShares Russell 2000 Growth ETF
0.08%
Optimize Strategy Index ETF
0.07%
查看更多
ALPS Medical Breakthroughs ETF
占比1.02%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.94%
SPDR S&P Biotech ETF
占比0.43%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.25%
ProShares Ultra Nasdaq Biotechnology
占比0.17%
Invesco Nasdaq Biotechnology ETF
占比0.17%
iShares Biotechnology ETF
占比0.12%
T Rowe Price Small-Mid Cap ETF
占比0.08%
iShares Russell 2000 Growth ETF
占比0.08%
Optimize Strategy Index ETF
占比0.07%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
